IOVA Iovance Biotherapeutics Inc

Lion Biotechnologies (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that Dr. Laszlo Radvanyi is leaving his position of chief scientific officer of the company.

"We are grateful for Laszlo's service to the company over the past year," stated Dr. Elma Hawkins, president and chief executive officer of Lion Biotechnologies. "During his tenure, we significantly increased our staff of scientists, established GMP manufacturing for TIL, filed our first IND, and opened our Phase 2 clinical trial in metastatic melanoma." She added, "We thank Laszlo for assisting us in our achievement of these milestones and wish him the best in his next endeavor."

"The data generated to date by the NIH and others demonstrating durable complete remissions with TIL therapy in melanoma is exciting," stated Dr. Laszlo Radvanyi. "I am proud to have built a strong research team at Lion and I am confident they will continue to develop new and exciting approaches within TIL research." He concluded, "I wish my colleagues at Lion well in their future efforts to commercialize this important new immuno-oncology therapy for patients across multiple solid tumor indications."

About Lion Biotechnologies

Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) for the treatment of patients with refractory metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center. For more information, please visit http://www.lionbio.com.

Forward Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties described in the Company's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Investor Relations
         The Trout Group
         Gitanjali Ogawa
         646-378-2949
         Gogawa@troutgroup.com